119 related articles for article (PubMed ID: 27703029)
1. New twists in the AXL(e) of tumor progression.
Halmos B; Haura EB
Sci Signal; 2016 Oct; 9(448):fs14. PubMed ID: 27703029
[TBL] [Abstract][Full Text] [Related]
2. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
4. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
[TBL] [Abstract][Full Text] [Related]
5. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
[TBL] [Abstract][Full Text] [Related]
6. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
Hua W; Zhao Y; Jin X; Yu D; He J; Xie D; Duan P
Gynecol Oncol; 2018 Nov; 151(2):356-365. PubMed ID: 30249526
[TBL] [Abstract][Full Text] [Related]
7. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
[TBL] [Abstract][Full Text] [Related]
8. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.
Niu ZS; Niu XJ; Wang WH
Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.
Yeh CY; Shin SM; Yeh HH; Wu TJ; Shin JW; Chang TY; Raghavaraju G; Lee CT; Chiang JH; Tseng VS; Lee YC; Shen CH; Chow NH; Liu HS
BMC Cancer; 2011 Apr; 11():139. PubMed ID: 21496277
[TBL] [Abstract][Full Text] [Related]
10. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
[TBL] [Abstract][Full Text] [Related]
11. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
[TBL] [Abstract][Full Text] [Related]
13. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
[TBL] [Abstract][Full Text] [Related]
15. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
Commun Biol; 2023 Jun; 6(1):660. PubMed ID: 37349576
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
[TBL] [Abstract][Full Text] [Related]
17. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
18. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
Gioia R; Trégoat C; Dumas PY; Lagarde V; Prouzet-Mauléon V; Desplat V; Sirvent A; Praloran V; Lippert E; Villacreces A; Leconet W; Robert B; Vigon I; Roche S; Mahon FX; Pasquet JM
J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
[TBL] [Abstract][Full Text] [Related]
19. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
